公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2014 | Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: Despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverse | SUNG-HSIN KUO ; Tsai H.-J.; Weng W.-H.; Li C.-C.; KUN-HUEI YEH ; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 3 | 3 | |
1998 | Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma | ANN-LII CHENG ; KUN-HUEI YEH ; Fine R.L.; Chuang S.-E.; Yang C.-H.; Wang L.-H.; DING-SHINN CHEN | Hepato-Gastroenterology | 41 | 33 | |
1989 | Bone marrow involvement in non-Hodgkin's lymphoma. | HONG-SHIEE LAI ; HWEI-FANG TIEN ; Hsieh H.C.; YAO-CHANG CHEN ; Su I.J.; Wang C.H.; Liu M.C.; ANN-LII CHENG ; MING-CHING SHEN ; Liu C.H. | Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association | 11 | 0 | |
2012 | Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A | CHAO YUAN HUANG ; CHIA-CHENG WEI ; Chen K.-C.; Chen H.-J.; ANN-LII CHENG ; Chen K.-F. | Cancer Letters | 29 | 28 | |
2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
2011 | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A | Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; PEI-JER CHEN ; ANN-LII CHENG | Molecular Cancer Therapeutics | 36 | 32 | |
2016 | BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer | KUO-HSING CHEN ; Lin Y.-L.; JAU-YU LIAU ; JIA-HUEI TSAI ; LI-HUI TSENG ; LIANG-IN LIN ; JIN-TUNG LIANG ; BEEN-REN LIN ; JI-SHIANG HUNG ; YIH-LEONG CHANG ; KUN-HUEI YEH ; ANN-LII CHENG | Medical Oncology | 19 | 18 | |
2008 | Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells | Lin H.-J.L.; Zuo T.; CHING-HUNG LIN ; Chieh T.K.; Liyanarachchi S.; Sun S.; Shen R.; Deatherage D.E.; Potter D.; Asamoto L.; Lin S.; Yan P.S.; ANN-LII CHENG ; Ostrowski M.C.; Huang T.H.-M. | Cancer Research | 58 | 55 | |
2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 618 | 595 | |
2022 | Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review | Graham, Jeffrey; Vogel, Arndt; ANN-LII CHENG ; Bjarnason, Georg A; Neal, Joel W | Cancer treatment reviews | 2 | 2 | |
2020 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG ; Rimassa L. | Future Oncology | 50 | 49 | |
2018 | Cabozantinib in patients with advanced and progressing hepatocellular carcinoma | Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG ; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. | New England Journal of Medicine | 1553 | 1405 | |
2022 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial | Kelley, Robin Kate; Rimassa, Lorenza; ANN-LII CHENG ; Kaseb, Ahmed; Qin, Shukui; Zhu, Andrew X; Chan, Stephen L; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Banerjee, Kamalika; Hazra, Saswati; Fawcett, Jonathan; Yau, Thomas | The Lancet. Oncology | 210 | 185 | |
2024 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study | Yau, Thomas; Kaseb, Ahmed; ANN-LII CHENG ; Qin, Shukui; Zhu, Andrew X; Chan, Stephen L; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Milwee, Steven; Wang, Zhong; Curran, Dominic; Kelley, Robin Kate; Rimassa, Lorenza | The lancet. Gastroenterology & hepatology | 2 | | |
2023 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study | Qin, Shukui; Chan, Stephen L; Gu, Shanzhi; Bai, Yuxian; Ren, Zhenggang; Lin, Xiaoyan; Chen, Zhendong; Jia, Weidong; Jin, Yongdong; Guo, Yabing; Hu, Xiaohua; Meng, Zhiqiang; Liang, Jun; Cheng, Ying; Xiong, Jianping; Ren, Hong; Yang, Fang; Li, Wei; Chen, Yajin; Zeng, Yong; Sultanbaev, Alexander; Pazgan-Simon, Monika; Pisetska, Margaryta; Melisi, Davide; Ponomarenko, Dmitriy; Osypchuk, Yurii; Sinielnikov, Ivan; Yang, Tsai-Sheng; Liang, Xiao; Chen, Chunxia; Wang, Linna; ANN-LII CHENG ; Kaseb, Ahmed; Vogel, Arndt; CHIUN HSU | Lancet (London, England) | 67 | 16 | |
2013 | Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome | Yu H.-C.; Hou D.-R.; Liu C.-Y.; Lin C.-S.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F. | PLoS ONE | 40 | 93 | |
2008 | Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway | Dai H.-Y.; Hong C.-C.; Liang S.-C.; Yan M.-D.; Lai G.-M.; ANN-LII CHENG ; Chuang S.-E. | Molecular Carcinogenesis | 38 | 35 | |
2020 | A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women | Lien, Guang-Wen; WU-SHIUN HSIEH ; WEN-HUNG KUO ; CHING-HUA KUO ; Huang, Ching-Chun; YUE-LIANG GUO; DWANG-YING CHANG ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; ANN-LII CHENG ; CHING-HUNG LIN ; PAU-CHUNG CHEN | Environment International | 48 | 35 | |
2015 | Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations | YI-HSIN LIANG ; Lin Y.-L.; JAU-YU LIAU ; JIA-HUEI TSAI ; JIN-TUNG LIANG ; BEEN-REN LIN ; JI-SHIANG HUNG ; LI-HUI TSENG ; LIANG-IN LIN ; YIH-LEONG CHANG ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 4 | 4 | |
2020 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | ANN-LII CHENG ; CHIUN HSU ; Chan S.L.; Choo S.-P.; Kudo M. | Journal of Hepatology | 297 | 267 | |